Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,244 recruiting studies in this area right now.
By phase
- Not applicable9,548
- Phase 24,415
- Phase 12,680
- Phase 1/Phase 21,655
- Phase 31,398
- Phase 2/Phase 3284
- Phase 4264
Top conditions
- Breast Cancer1,202
- Prostate Cancer646
- Cancer634
- Colorectal Cancer481
- Lung Cancer418
- Ovarian Cancer339
- Multiple Myeloma330
- Pancreatic Cancer292
- Gastric Cancer283
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma256
- Solid Tumor247
- Advanced Solid Tumor233
- Head and Neck Cancer227
- Cervical Cancer225
- Endometrial Cancer211
- Advanced Solid Tumors203
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center454
- Fudan University305
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center291
- Sun Yat-sen University275
- Mayo Clinic238
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences144
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,412
- Texas636
- Arizona507
- Florida438
- Alabama428
- New York407
- Massachusetts342
- Maryland329
- New Jersey273
- Pennsylvania235
Recruiting studies20,244 total
- NCT06156579RecruitingPhase 2
Venetoclax and Decitabine for Relapsed or Refractory AML
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
Tübingen, Baden-WurttembergAges 18 years+ - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT07219459RecruitingPhase 2
New drug combo for liver cancer after PD-1/PD-L1 treatment fails
This study tests three drugs (visugromab, nivolumab, lenvatinib) compared to a placebo plus lenvatinib for people with liver cancer (HCC) that cannot be removed or has spread, and who have already been treated with a PD-1/PD-L1 inhibitor without success. The goal is to see if the combination can help shrink tumors or slow the cancer.
Irvine, CaliforniaAges 18–100 - NCT07217587RecruitingPhase 3
Comparing two drugs for generalized myasthenia gravis
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
Fullerton, CaliforniaAges 18–74 - NCT07219277Recruiting
Blood test to detect breast cancer early in women
This study tests a new blood test that aims to find breast cancer early in women who are at higher risk or are going for routine screening. If you are a woman aged 30–75 and are scheduled for a mammogram, MRI, or breast ultrasound, you may be able to help validate this test.
Phoenix, ArizonaAges 30–75 - NCT07216443RecruitingPhase 2
Study of orca-t for leukemia or MDS with reduced intensity chemo
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
Los Angeles, CaliforniaAges 18 years+ - NCT07215637RecruitingPhase 1
CKD-512 with or without pembrolizumab for advanced solid tumors
This trial tests a new drug, CKD-512, alone or combined with pembrolizumab, in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if this therapy can help when other options are no longer working.
SeoulAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Birmingham, AlabamaAges 18 years+ - NCT07220863Recruiting
Breast mapping test for finding suspicious spots
This trial tests a new Feminai device that maps breast tissue to find suspicious lumps. If you're coming for a routine mammogram or a biopsy, this could help improve detection.
Frisco, TexasAges 25–75 - NCT07213609RecruitingPhase 1/Phase 2
Study of GSK5460025 for advanced solid tumors
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Aurora, ColoradoAges 18 years+ - NCT07221253RecruitingPhase 3
Study of Rilvegostomig or Durvalumab plus chemo for biliary tract cancer
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
Birmingham, AlabamaAges 18 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07219212RecruitingPhase 1
New drug with chemo and radiation for advanced head and neck cancer
This study tests if adding an investigational drug called JNJ-90301900 to standard chemotherapy and radiation therapy works better for people with certain advanced head and neck cancers (like mouth, throat, and voice box) that have not spread to other parts of the body.
Birmingham, AlabamaAges 18–74 - NCT07216105RecruitingPhase 1
New immune cell treatment for advanced solid tumors
This trial tests a new treatment using specially engineered immune cells (called FT836) for people with advanced solid tumors that have not responded to other treatments. It may be given alone or with chemotherapy and/or other antibody medicines. The study aims to see if this approach can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT07219238RecruitingPhase 2/Phase 3
PET scan for cancer spread in the abdomen
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Grand Rapids, MichiganAges 18 years+ - NCT07218926RecruitingPhase 3
New drug vs sunitinib for GIST after imatinib
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
Phoenix, ArizonaAges 18 years+ - NCT07221331Recruiting
Neurofibromatosis type 1 study in Egypt
This study looks at how neurofibromatosis type 1 (NF1) affects people in Egypt, including how it progresses and how it is managed. Researchers will review medical records of patients diagnosed with NF1 between 2010 and 2023 to learn more about the condition.
Al MansurahAges Any age - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT07218341RecruitingPhase 4
Continuing pirtobrutinib for CLL or SLL patients
This trial continues treatment with the drug pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already in another study. It is not open to new patients.
Mobile, AlabamaAges 18 years+ - NCT07213817RecruitingPhase 1/Phase 2
Safety and effectiveness of IPN60300 for advanced solid tumors
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07216560RecruitingPhase 1/Phase 2
Testing a new drug for advanced stomach or bowel cancer
This trial tests a new drug called 7MW4911 for people with advanced gastrointestinal cancer that has not responded to standard treatments. The drug is designed to target and attack cancer cells, and doctors will check if it is safe and effective.
Port Saint Lucie, FloridaAges 18 years+ - NCT07215585RecruitingPhase 3
New targeted therapy for elderly or unfit lymphoma patients
This trial tests a new targeted therapy (AZD0486) as a first treatment for older or less fit people with large B-cell lymphoma. It is for those who cannot tolerate the usual strong chemo, aiming to be gentler while still fighting the cancer.
ClaytonAges 65–130 - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Phoenix, ArizonaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,244 recruiting oncology studies from the U.S. registry right now, out of 30,552 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.